Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Newron Pharmaceuticals SpA
Discovers and develops small molecule drugs

Newron Pharmaceuticals SpA engages in the research and development of drugs for the treatment of central nervous system disorders and pain.

It operates through a single segment which is the Research and Development of Pharmaceutical drugs.

The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Number of employees : 23 persons.
Sales per Businesses
20122013Delta
CHF (in Million)%CHF (in Million)%
Pharmaceuticals10.73100%3.95100% -171.43%
Managers
NameAgeSinceTitle
Stefan Weber492005Chief Executive Officer, MD, Director & IR Contact
Ulrich Köstlin, PhD622013Non-Executive Chairman
Roberto Galli-2002VP-Finance & Investor Relations Contact
Ravi Anand, MD572005Chief Medical Officer
Patrick J. Langlois, PhD682008Independent Director
Hanns Moehler, MD-2008Non-Executive Director
Roberto Consonni-2012Non-Executive Director
Robert Leslie Holland MD, PhD592013Non-Executive Director
Bo Jesper Hansen MD, PhD552013Non-Executive Director
Marco Caremi572002Executive Vice President-Business Development
Shareholders
NameShares%
Investor AB 1,665,73312.8%
Gefim SpA 1,484,19511.4%
JPMorgan Asset Management (UK) Ltd. 611,4734.69%
Swisscanto Asset Management AG 204,5031.57%
Aviva Investors Global Services Ltd. 115,6950.89%
Polar Capital LLP 109,7310.84%
Credit Suisse AG 58,8700.45%
Michel & Cortesi Asset Management AG 55,2140.42%
Entrepreneur Partners AG 48,0000.37%
UBS AG (Investment Management) 31,2700.24%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Surperformance© rating
Overall rating
Trading Rating -
Investor Rating -
Growth (Revenue) -
Valuation -
Finances
Profitability
Earnings quality
Business Predictability -
PER -
Potential -
Yield -
Consensus -
7 days EPS revision -
4 months EPS revision -
1 year EPS revision -
4 months Revenue revision -
1 year Revenue revision
More Ratings
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
RECEPTOS INC
NPS PHARMACEUTICA..
AGIOS PHARMACEUTI..
INTERCEPT PHARMAC..
HUALAN BIOLOGICAL..
TONGHUA DONGBAO P..
BEIJING SL PHARMA..
AVANIR PHARMACEUT..
GENMAB A/S
MANNKIND CORPORAT..
DYAX CORP.
CHINA BIOLOGIC PR..
CLOVIS ONCOLOGY I..
GW PHARMACEUTICAL..
ACORDA THERAPEUTI..
NEUROCRINE BIOSCI..
PTC THERAPEUTICS,..
Sector Biotechnology & Medical Research
Company contact information
Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso, Milan 20091

Phone : +39.02.610.3461
Fax : +39.02.610.34654
Web : www.newron.com
© 2014 Factset   
Dynamic quotes  
ON
| OFF